Actively Recruiting
Phase III Study Comparing XNW28012 With Placebo Alongside Best Supportive Care for Patients With Metastatic Pancreatic Cancer After Prior Systemic Therapy
Led by Evopoint Biosciences Inc. · Updated on 2026-09-16
226
Participants Needed
48
Research Sites
13 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating XNW28012, a drug being studied for treatment in patients with metastatic pancreatic ductal carcinoma who have not responded to or cannot tolerate two prior standard treatments. This phase III, randomized, double-blind, multicenter study compares XNW28012 against a placebo mimetic, both given alongside optimal supportive care including nutritional support and pain management. Participants are randomly assigned in a 21 ratio to receive either XNW28012 at a dose of 2.4 mgkg every three weeks or the placebo mimetic on the same schedule. Both groups receive best supportive care throughout the study. The treatment period continues while monitoring responses and safety. The study includes comprehensive evaluation of disease progression and treatment effects over an average of two years. During the study, participants undergo regular assessments including imaging and laboratory tests to evaluate tumor response, disease control, and adverse events. Researchers measure survival time from enrollment until death from any cause, along with progression-free survival and other response-related outcomes. Safety monitoring includes tracking adverse events and drug antibody levels. Participants remain in the study for about two years on average, with follow-up to collect outcome data.
CONDITIONS
Brief Title
Study of XNW28012 in Subjects With Metastatic Pancreatic Cancer Who Received Prior Systemic Therapy
Research Team
Y
Yingjie zhao
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here